SNWV logo

SNWV

SANUWAVE Health, Inc.NASDAQHealthcare
$16.90+0.30%ClosedMarket Cap: $145.2M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

12.30

PEG

0.09

P/B

90.50

P/S

3.34

EV/EBITDA

25.38

DCF Value

$-48.85

FCF Yield

2.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.1%

Operating Margin

11.2%

Net Margin

26.8%

ROE

-141.6%

ROA

31.6%

ROIC

19.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$13.1M$6.1M$0.02
FY 2025$44.1M$11.8M$0.41
Q3 2025$11.5M$10.3M$1.13
Q2 2025$10.2M$1.1M$0.01

Analyst Ratings

View All
Roth CapitalBuy
2026-03-30
Roth CapitalBuy
2025-08-22

Trading Activity

Insider Trades

View All
MANCHESTER MANAGEMENT CO LLCother: Director by Deputization
SellMon Dec 15
MANCHESTER MANAGEMENT CO LLCother: Director by Deputization
SellMon Dec 15
MANCHESTER MANAGEMENT CO LLCother: Director by Deputization
SellWed Dec 10
MANCHESTER MANAGEMENT CO LLCother: Director by Deputization
SellWed Dec 10
MANCHESTER MANAGEMENT CO LLCother: Director by Deputization
SellWed Dec 10

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

1.51

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Peers